Q-omics provides the consensus-scored PHBP19 profile across patient tissues and cancer cell-line models. PHBP19 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PHBP19 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, PHBP19 RNA expression shows 16,585 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where PHBP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP19 survival associations across molecular data types. PHBP19 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP19 RNA expression–survival associations across cancer types. High PHBP19 expression shows unfavorable associations in KIRC, CESC, UVM, MESO and THCA, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PHBP19 RNA expression.
This table summarizes PHBP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP19 shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, CHOL, READ and STAD. The LIHC box plot shows higher PHBP19 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .001).
This table shows molecular features associated with PHBP19 in patient tissues and cancer cell lines. In patient samples, PHBP19 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
